帕立骨化醇治疗尿毒症继发性甲状旁腺功能亢进症的临床效果分析

Effect analysis of paricalcitol in the treatment of uremic secondary hyperparathyroidism

目的分析帕立骨化醇治疗尿毒症继发性甲状旁腺功能亢进症的临床效果。方法70例尿毒症继发性甲状旁腺功能亢进症患者,随机分为对照组及观察组,各35例。对照组患者给予骨化三醇治疗,观察组患者给予帕立骨化醇治疗。比较两组患者的治疗效果,治疗前后的甲状旁腺激素、钙、磷水平,高钙血症发生情况。结果观察组患者的总有效率94.29%高于对照组的74.29%,差异具有统计学意义(P<0.05)。治疗后,观察组患者的甲状旁腺激素(378.02±13.01)pg/ml、磷(1.62±0.11)mmol/L低于对照组的(655.01±67.12)pg/ml、(2.15±0.32)mmol/L,钙(2.35±0.31)mmol/L高于对照组的(1.87±0.12)mmol/L,差异具有统计学意义(P<0.05)。观察组患者的高钙血症发生率2.86%低于对照组的20.00%,差异具有统计学意义(P<0.05)。结论帕立骨化醇治疗尿毒症继发性甲状旁腺功能亢进症的效果确切,可有效降低甲状旁腺激素水平和磷水平,提高钙离子水平,降低高钙血症的发生,安全性高。

Objective To analyze the clinical effect of paricalcitol in the treatment of uremic secondary hyperparathyroidism.Methods A total of 70 patients with uremic secondary hyperparathyroidism were randomly divided into control group and observation group,with 35 cases in each group.Patients in the control group were treated with calcitriol,and patients in the observation group were treated with paricalcitol.Patients in both groups were compared in terms of therapeutic effect,levels of parathyroid hormone,calcium and phosphorus before and after treatment,and the occurrence of hypercalcemia.Results The total effective rate 94.29%in the observation group was higher than 74.29%in the control group,and the difference was statistically significant(P<0.05).After treatment,the parathyroid hormone(378.02±13.01)pg/ml and phosphorus(1.62±0.11)mmol/L of the observation group were lower than(655.01±67.12)pg/ml and(2.15±0.32)mmol/L of the control group,and the calcium(2.35±0.31)mmol/L was higher than(1.87±0.12)mmol/L of the control group.All the differences were statistically significant(P<0.05).The incidence of hypercalcemia 2.86%in the observation group was lower than 20.00%in the control group,and the difference was statistically significant(P<0.05).Conclusion Paricalcitol has significant effect on uremic secondary hyperparathyroidism,and it can reduce the level of parathyroid hormone and phosphorus,improve the level of calcium ion,and reduce the incidence of hypercalcemia with high safety.